Nexalin signs exclusive Brazil and South America distribution agreement
Nexalin Technology entered a 10-year exclusive distribution agreement, effective September 22, 2026, with Inovanexa Medical Technologies S.A. for its Nexalin Sync device in seven countries. The filing discloses no purchase value or revenue figures, and the company says it is pre-revenue, so the financial effect for shareholders depends on purchase orders and the performance requirements that the distributor must meet.
Key points
- Exclusivity covers Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, with a 10-year initial term that renews automatically if performance requirements are met.
- The 8-K says the distributor must place an initial binding order for five devices at signing, with a clinical pilot targeted within 90 days. The press release says the binding order is for 10 devices, with five delivered immediately.
- After the first 30 devices are purchased, the distributor must set up a local manufacturing facility in Brazil at its own cost, and Nexalin would receive per-device compensation and disposable royalties.
- The filing states the distributor is not otherwise obligated to buy more devices, and the company's risk disclosures say it may never recognize revenue beyond the initial order.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.